Cannabidivarin Research:
Relevant Publications
Below is a list of current research publications aiming to show the potential therapeutic effects of CBDV.
Studies:
- These results indicate that CBDV is an effective anticonvulsant in a broad range of seizure models. Also it did not significantly affect normal motor function and, therefore, merits further investigation as a novel anti-epileptic in chronic epilepsy models, British Journal of Pharmacology: LINK
- Research on humans who had self administered cannabinoids supported this notion (anti-seizure), revealing a link between CBDV, fewer seizures, and improved cognitive recovery, Epilepsia Open: LINK
- In early 2019, an animal study showed that CBDV reduced autism-like behavior in rats by restoring brain function to fix social impairments, short-term memory deficits, repetitive behaviors and more, Front Cell Neuroscience: LINK
- A study on a small group of humans supported the notion that CBDV could protect brain function to ameliorate symptoms of autism spectrum disorder, Translational Psychiatry: LINK
- A 2019 study observed that CBDV reduced intestinal inflammation in animals and lessened cytokine expression in biopsied human tissue. Together these facts suggested that CBDV could effectively treat ulcerative colitis (UC). Given CBDV’s favorable safety profile, the authors of the study argued that the cannabinoid should be considered for clinical trials in patients with UC, Pharmacological Research Journal: LINK
- A 2018 animal study found that CBDV countered the neurodegenerative symptoms of Retts disease, Journal of Nueropharmacology: LINK
- Another animal study from 2019 found that the cannabinoid rescued cognitive deficits and delayed neurological and motor defects in diseased mice, Journal of Psychopharmacology: LINK